【柳氮磺吡啶疗效】柳氮磺吡啶对强直性脊柱炎作用机制是什么?效果如何?

After the symptoms of ankylosing spondylitis occur, patients will have symptoms such as fatigue, weight loss, low fever, and anorexia. If the symptoms of ankylosing spondylitis cannot be treated and controlled promptly and effectively. Then there are also lesions that may affect the patient's lumbar spine, thoracic spine, cervical spine and surrounding joints. In addition to affecting the joints, it can also affect the patient's heart, ears, eyes, lungs, nerves and other tissues. It is a very serious malignant bone disease. Sulfasalazine still has a certain effect in treating the symptoms of ankylosing spondylitis, and it can be used to treat the symptoms of ankylosing spondylitis. What is the mechanism of action of sulfasalazine on ankylosing spondylitis? What is its effect?

Mechanism of action of sulfasalazine

Sulfasalazine is an azo compound of salicylic acid and sulfapyridine, which has antibacterial, antirheumatic and immunosuppressive effects. It is broken down by bacteria in the intestine into sulfapyridine (SP) and 5-aminosalicylic acid (5-ASA). SP has a weak antibacterial effect. It mainly acts as a carrier in drug molecules, preventing the absorption of 5-ASA in the stomach and duodenum. Only under alkaline conditions in the intestine, intestinal microorganisms rupture the diazo bonds and release the active ingredients. The mechanism is currently believed to be that 5-ASA complexes with the connective tissue of the large intestinal wall and stays in the intestinal wall tissue for a long time to play antibacterial, anti-inflammatory and immunosuppressive effects, reduce Escherichia coli and Clostridium, and inhibit the synthesis of intestinal prostaglandins (prostaglandins are increased in patients with ulcerative colitis) and the synthesis of other inflammatory mediators (leukotrienes). Its anti-rheumatic effect may be produced by sulfapyridine inhibiting certain antigenic substances in the intestine, thereby inhibiting the immune process of ankylosing spondylitis and rheumatoid arthritis. Sulfasalazine has little absorption from the gastrointestinal tract, has a special affinity for connective tissue, and releases sulfapyridine from the connective tissue of the intestinal wall.

Sulfasalazine therapeutic effect

Objective To analyze the clinical effect of sulfasalazine combined with thalidomide in the treatment of ankylosing spondylitis. 124 patients with ankylosing spondylitis were divided into a study group and a control group according to the random number table method, with 62 cases in each group. The control group received sulfasalazine treatment, and the research group received thalidomide treatment on the basis of the control group. Both groups were treated continuously for 6 months. The total effective rate of treatment and the incidence of adverse reactions were compared between the two groups. Results: The total effective rate of treatment in the study group was 91.94%, which was higher than that in the control group, 74.19%; there was no statistically significant difference in the incidence of adverse reactions between the two groups. Conclusion Sulfasalazine combined with thalidomide has significant clinical effect in the treatment of ankylosing spondylitis, and can effectively improve the clinical symptoms of patients and improve the therapeutic effect.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: